This cohort study of 22 101 patients with NSCLC found that increased targeted therapy use for patients with nonsquamous cancer with EGFR sequence variants or ALK rearrangement in period 2 (2017-2019) was associated with better OS than for similar patients in period 1 (2014-2016). This evidence concerns the gene ALK and cancer.